In December, the two pharmaceutical giants announced that they would form a joint venture combining their consumer health business. GSK will own 68 percent of the new venture which is anticipated to have combined sales of approximately £9.8 billion.

The new consumer healthcare venture will align with GSK’s long-term vision to strengthen its pharmaceuticals business over the next few years by increasing cash flow and effectively investing in its R&D pipeline. 

ACCC approved the deal after conducting ‘market inquiries and analysing data’ provided by GSK and Pfizer. ACCC Commissioner Roger Featherston said in a statement that the combined business will face competition owing to a ‘range of generic options’ for consumers. For example: GSK’s famous medicine Panadol will face tough competition from Reckitt Benckiser’s Nurofen.

The companies’ new venture will establish its presence in all key regions, such as the US, Western, Central and Eastern Europe, China, India, and Australasia, the GSK press release stated.

The post Australia approves GSK, Pfizer consumer healthcare venture merger appeared first on International Finance.

The commission announced the reviews in a submission to the government’s chief economic advisory body, which was published on Tuesday. The reviews follow an ongoing judicial inquiry into Australia’s financial sector, which has already revealed that banks abused their power and routinely breached laws while issuing home loans, credit cards and other consumer loans.

In one of its first uses of the new powers, an interim inquiry in March on the mortgage pricing mechanisms of the banks and Macquarie Group found signs of “accommodative oligopoly behaviour”. The ACCC’s final report is due on June 30. The organisation is also expected to examine recent claims made by the Productivity Commission, the government’s chief economic advisor, that policy interventions by the banking regulator to curb asset bubbles had delivered record profits for the banks at the expense of competition, added Reuters.

In February, the Productivity Commission also recommended the ACCC should be a member of the Council of Financial Regulators, which is chaired by the central bank and holds the main responsibility of financial system oversight, to act as “the competition champion”.

Australia’s big four banks reported a combined net profit of US$24.5bn in the 2017 fiscal year, up 6.4% on a year ago, according to KPMG.

The post ACCC to review power of Australia’s big four banks appeared first on International Finance.